Fondazione Telethon Ets
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
Previously recorded as Fondazione Telethon (to 2023)
1
Ending by 2030
Dec 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 19, 2027The maintenance fee for Compounds for Use in Polycystic Kidney Disease (US 10,478,446) comes due May 19, 2027. Unpaid by Nov 19, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Tolerogenic dendritic cells, method for their production and uses therof (US 9,234,174) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 2 fees due Oct 16 to 23, 2027 · next Oct 16
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,234,174 | Tolerogenic dendritic cells, method for their production and uses therof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,260,042 | Compositions and Methods for Diminishing an Immune Response In force · High confidence | In force | High confidence | |
| US 10,478,446 | Compounds for Use in Polycystic Kidney Disease In force · High confidence | In force | High confidence | |
| US RE50,283 | Effective delivery of large genes by dual AAV vectors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,912,824 | Vector Production In force · High confidence | In force | High confidence | |
| US 11,957,747 | Vector Production In force · Low confidence | In force | Low confidence | |
| US 12,485,187 | Method for Improving Retroviral Transduction and Gene Editing in Hematopoietic Stem Cells Using Clyclosporin H and UM171 In force · High confidence | In force | High confidence | |
| US 12,059,478 | Gene Therapy In force · High confidence | In force | High confidence | |
| US 12,076,330 | Inhibition of Lipofuscin Aggregation by Molecular Tweezers In force · High confidence | In force | High confidence | |
| US 12,076,332 | Treatment of Lysosomal Storage Disorders In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 3 no status recorded